What's Next for Iovance Biotherapeutics Stock?
Depending on which facts you choose to focus on, you could have widely varying opinions on Iovance Biotherapeutics (NASDAQ: IOVA). From one perspective, it's an ailing biotech that's facing down the specter of serious -- potentially existential -- risks inherent to the focus of its scientific platform. In the sunnier view, it's a budding biotech that's on the verge of blasting off as a result of its sensible yet aggressive drug development.
Which narrative will carry the day? Charting a course for this stock over the next couple of years requires appreciating what challenges and opportunities the company is facing, as well as understanding which facts will be the most relevant for its financial performance.
Iovance's shares are down by 82% over the last three years, and it doesn't yet have any internally developed medicines on the market. It may also face a bumpy road in moving at least some of its candidates to the commercial stage as a result of a recent tragedy.
Source Fool.com
